Wall Street Trader 3 juli 2019 10:28 auteur info Wall Street Trader Lid sinds: 09 aug 2018 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 3455 Gegeven: 1213 Aantal posts: 1.253 JefferiesGILEAD SCIENCESContinued Good News on Improving Story (Filgotinib)July 1, 2019Key TakeawayGILD announced incrementally positive news that supports our view that things are getting relatively better and the story is turning around. Based on a pre-NDA meetingand a discussion with the FDA around the recent positive Phase III data and the ongoingPhase II male toxicity study (MANTA), GILD announced that the FDA agreed there is apath forward to file an NDA for filgotinib in 2019.This is an incremental positive surprise as the Street has been uncertain about whethera filing in 2019 was even possible. When filgotinib's pivotal program started, the agencysaid GILD was required to complete the male toxicity study, which had been enrollingvery slowly and therefore suggested an NDA filing later in 2020. Today's announcementmakes a filing more likely to occur later this year, so GILD is not that far behind ABBVwhich filed around 6 months ago. An outstanding question is whether GILD has a priorityreview voucher handy and thus can keep the timing tight, since ABBV used a priorityvoucher for upadacitinib to expedite the regulatory decision to Q3:19.To be balanced and fair, we acknowledge from GILD's press release that there is a"path forward" to filing in 2019. It appears to us that the conversation would be likelyconducting an interim pooled analysis in Q3 so that they could file upon that event. Otheroutstanding questions are of course if the male toxicity study turned out to be positiveor negative and whether that would impact GILD's ability to file. If positive, we wouldcertainly argue everything would be very good and GILD would be very competitive if notbest-in-class compared to ABBV. If data was negative and the drug did cause a reductionin sperm count, this scenario wouldn't appear to block GILD's ability to file. Rather, itwould be an issue in the label, which isn't too commercially relevant in our opinion giventhat these indications comprise of mostly females. Aanbevelingen 2 ” Quote Reageren Niet oké
Lama Daila 3 juli 2019 11:46 auteur info Lama Daila Lid sinds: 11 aug 2015 Laatste bezoek: 27 apr 2023 Aanbevelingen Ontvangen: 2112 Gegeven: 158 Aantal posts: 707 quote:Lama Daila schreef op 30 juni 2019 16:19:www.researchpool.com/provider/bryan-g...Bryan Garnier: GALAPAGOS | Buy | FV EUR140 | (MANTA) With or Without YouGilead is heading into a pre-BLA meeting to discuss data from the FINCHes trials and the filing timelines for filgotinib. The outcome of this meeting should be communicated in the coming weeks.De link naar de volledige nota stond in de recente nota die AvantiAvanti hier plaatste:medias.bryangarnier.com/equity/pdf/FO... Aanbevelingen 2 ” Quote Reageren Niet oké
harvester 3 juli 2019 15:46 auteur info harvester Lid sinds: 01 apr 2004 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 2006 Gegeven: 1885 Aantal posts: 4.184 Na de nu bekende updates gelezen te hebben, vind ik de updates wel positief, maar vindt de aanpassing van de koersdoelen wat beperkt. Ik had wel wat meer verwacht.Dat GS houden zegt en het koersdoel niet opkrikt naar de huidige koers vind ik wat tegenstrijdig "to put it mildly", zeker nadat Galapagos ook op hun conferentie present is geweest. Wellicht willen veel banken de 2e kwartaal rapportages van Gilead afwachten en daarbij mogelijk nieuws over het al of niet inzetten van de priority review.Als ik mij niet vergis kunnen wij nog updates verwachten van een 3 tal banken waaronder Berenberg. Wellicht dat die wel wat aan hun koersdoel doet. Aanbevelingen 0 ” Quote Reageren Niet oké
avantiavanti 9 juli 2019 09:57 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 Citi 9 juli 2019Verhoogt pt van 115 euro naar 140 euroRaising Price Target to €140 on Likely Filgotinib US Filing in 2019 Aanbevelingen 14 ” Quote Reageren Niet oké
MtBaker 15 juli 2019 07:48 auteur info MtBaker Lid sinds: 22 dec 2006 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 658 Gegeven: 1467 Aantal posts: 7.819 jp morgan 165 euro doel gezien deal. Aanbevelingen 2 ” Quote Reageren Niet oké
[verwijderd] 15 juli 2019 10:30 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 www.researchpool.com/provider/bryan-g...Bryan Garnier 180 euro (van 140 euro). Aanbevelingen 1 ” Quote Reageren Niet oké
avantiavanti 15 juli 2019 10:45 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 Kempen 15 juli 2019This is how you do it.Gilead and Galapagos entered a collaboration granting Gilead optionsfor ex-EU rights for anything coming from Galapagos' pipeline for thenext 10 years in exchange for $3.95b upfront, $1.1b equity investmentplus multibillion future milestones. In all, the deal seems like a totalwin-win for both parties where Gilead finally gets the late-stagepipeline and exciting R&D engine, and Galapagos gains a strong andcommitted commercial partner, who will help build Galapagos' owninfrastructure, and desired independence from takeover attemptsand financial markets, while further expanding the R&D to discovernovel targets. Just reflecting the upfront, equity investments and thenearterm milestones and royalties on the proprietary pipeline in ourmodel, without a potential commercial advantage from having Gileadas a partner, our PT goes to €180 ($160 for ADR) from €135 ($120).Galapagos continues to feature on our favorites list. Aanbevelingen 4 ” Quote Reageren Niet oké
avantiavanti 15 juli 2019 10:51 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 Extract uit Morgan Stanley update 15 juli 2019Long-term Collaboration Provides Opportunity for Both Gilead and GalapagosGilead and Galapagos announced a $5.1B, 10 year strategic partnership for exEU rights to Galapagos' pipeline. The deal provides Gilead with a proven target discovery engine and expanded late-stage pipeline. It enables Galapagos to grow its discovery engine and build an integrated biopharma co.Gilead and Galapagos announce a 10 year strategic pipeline transaction: Gilead will pay $3.95B upfront and buy $1.1B of Galapagos stock at a 20% premium to the 30 day weighted average price ( €140.59/share) for rights to Galapagos' pipeline outside of Europe for 10 years. The deal excludes MOR106. Specifically, Gilead has the right to opt-in to any program post-PhII for $150M upfront and 20-24% in royalties. Current clinical programs GLPG1690 and GLPG1972 are also included with the former carrying a $325M US approval milestone and the latter a $250M opt-in after PhIIb and up to $750M in milestones. All programs carry 50/50 cost-sharing post opt-in. The filgotinib deal has been restructured to include 50/50 global cost sharing and a 50/50 profit split with Galapagos in the EU5 (expanded from just Benelux region). Importantly, Gilead's equity investment in Galapagos will bring Gilead's ownership to ~22%. Gilead will receive two warrants to increase its ownership to 29.9%, subject to a shareholder vote. The first warrant, with a 1 year term, can increase Gilead's stake to 25% with a €140.59 strike price. The second warrant, with a 10 year term, can increase Gilead's stake to 29.9% and carries a 20% premium to Galapagos' stock price when exercised. The deal also includes a 10 year standstill.Impact to Gilead (EW, PT $83): The practical impact of this transaction is that it grows Gilead's mid-to-late stage pipeline in inflammatory diseases overnight, providing key potential catalysts in the early-to-mid-2020s. Importantly, it also significantly expands Gilead's discovery capabilities and delivers a potential steady stream of pipeline opportunities, an area that has been lacking at Gilead. Importantly, in our conversations with mgt. we believe the rationale for this deal was a portfolio approach to expanding the long-term pipeline at Gilead and does not rest on a single asset. However, just as important, mgt. indicated it will continue to look toward opportunities to rebuild Gilead's pipeline suggesting that this is not the only deal it will pursue. Overall we see the strategic rationale for the deal as solid and look forward to mgt.'s full strategic plan in the fall.Impact to Galapagos: We see three key impacts from this deal. First, Galapagos now has the capital to prosecute its broad pipeline, but maintains the independence of early clinical decisions so that it can continue to drive key programs into the clinic and through proof-of-concept quickly. Second, mgt. can now expand its target discovery engine from ~500 to ~1,000 scientists to drive higher through-put of novel targets which in turn can lead to an expanded clinical pipeline. Finally, the deal also accelerates mgt.'s goal of delivering an integrated biopharma organization which will have a strong European commercial presence. Together this expands Galapagos' clinical and commercial potential.Morgan Stanley is currently acting as a financial advisor to Galapagos N.V. (“Galapagos") in relation to its agreement to enter into a 10-year global collaboration with Gilead Sciences, Inc. that covers Galapagos’ current and future portfolio (the “Collaboration”), as announced on July 14, 2019.The proposed transaction is subject to required regulatory approvals and other customary closing conditions and certain elements of the Collaboration are subject to the approval of Galapagos’ shareholders. Galapagos has agreed to pay fees to Morgan Stanley for its services that are contingent upon the consummation of the proposed transaction. Aanbevelingen 2 ” Quote Reageren Niet oké
[verwijderd] 15 juli 2019 10:51 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:avantiavanti schreef op 15 juli 2019 10:45:Kempen 15 juli 2019This is how you do it.Gilead and Galapagos entered a collaboration granting Gilead optionsfor ex-EU rights for anything coming from Galapagos' pipeline for thenext 10 years in exchange for $3.95b upfront, $1.1b equity investmentplus multibillion future milestones. In all, the deal seems like a totalwin-win for both parties where Gilead finally gets the late-stagepipeline and exciting R&D engine, and Galapagos gains a strong andcommitted commercial partner, who will help build Galapagos' owninfrastructure, and desired independence from takeover attemptsand financial markets, while further expanding the R&D to discovernovel targets. Just reflecting the upfront, equity investments and thenearterm milestones and royalties on the proprietary pipeline in ourmodel, without a potential commercial advantage from having Gileadas a partner, our PT goes to €180 ($160 for ADR) from €135 ($120).Galapagos continues to feature on our favorites list.Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch? $180 en €160. Aanbevelingen 0 ” Quote Reageren Niet oké
MtBaker 15 juli 2019 11:11 auteur info MtBaker Lid sinds: 22 dec 2006 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 658 Gegeven: 1467 Aantal posts: 7.819 quote:C200 schreef op 15 juli 2019 10:51:[...]Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch? $180 en €160. tijd voor een bezoekje aan de brillennwinkel, maar het kijkt inderdaad te kloppen. Aanbevelingen 0 ” Quote Reageren Niet oké
Sir Piet 15 juli 2019 11:21 auteur info Sir Piet Lid sinds: 20 sep 2004 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 1117 Gegeven: 2858 Aantal posts: 3.816 quote:C200 schreef op 15 juli 2019 10:51:[...]Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch? $180 en €160. Ze houden er al rekening mee dat de euro flink in waarde daalt denk ik zo.............. Aanbevelingen 0 ” Quote Reageren Niet oké
Pokerface 15 juli 2019 11:24 auteur info Pokerface Lid sinds: 27 mrt 2001 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 1019 Gegeven: 1234 Aantal posts: 3.960 KBC verhoging:Beursblik: KBC Securities verhoogt koersdoel GalapagosRedactie De Aandeelhouder - maandag, 15 juli 2019Koopadvies behouden.(ABM FN) KBC Securities heeft maandag het koersdoel voor Galapagos maandag verhoogd van 128,00 naar 145,00 euro met een ongewijzigd koopadvies.Volgens analist Lenny Van Steenhuyse heeft Galapagos een "royale deal" met Gilead getekend. Deze overeenkomst geeft volgens de analist Galapagos nog eens tien jaar de tijd om met zijn Amerikaanse partner programma’s na te streven terwijl het de mogelijkheid biedt om commerciële expertise te ontwikkelen in Europa.Onder de uitgebreide samenwerking ontvangt Galapagos een vooruitbetaling van 3,95 miljard dollar en investeert Gilead voor 1,1 miljard dollar in aandelen. Galapagos gaat deze middelen inzetten om haar R&D-activiteiten uit te breiden en te versnellen.Naar aanleiding van het nieuws over de investering van Gilead in Galapagos en een aanzienlijke kasinstroom tegen eind 2019, KBC Securities mikt op een instroom van 0,5 miljard euro, besloot de analist tot de koersdoelverhoging.Het aandeel Galapagos koerste maandag kort na opening 17,3 procent hoger op 150,55 euro. Aanbevelingen 0 ” Quote Reageren Niet oké
Wall Street Trader 15 juli 2019 12:02 auteur info Wall Street Trader Lid sinds: 09 aug 2018 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 3455 Gegeven: 1213 Aantal posts: 1.253 Analyst Price Targets (Updated)RBC Sector Perform Price Target € 132Citigroup Smith Barney Price Target € 140JP Morgan Price Target € 165Kempen Price Target € 180KBC Price Target € 145Jefferies & Co. Price Target € 130Bryan Garnier & Co Price Target € 180 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 15 juli 2019 12:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:Wall Street Trader schreef op 15 juli 2019 12:02:Analyst Price Targets (Updated)RBC Sector Perform Price Target € 132Citigroup Smith Barney Price Target € 140JP Morgan Price Target € 165Kempen Price Target € 180KBC Price Target € 145Jefferies & Co. Price Target € 130Bryan Garnier & Co Price Target € 180Most of them are wrong.. but they'll catch up later. Aanbevelingen 0 ” Quote Reageren Niet oké
voda 15 juli 2019 12:49 auteur info voda Lid sinds: 02 dec 2005 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 92630 Gegeven: 22746 Aantal posts: 382.850 Video: heel positief nieuws voor GalapagosFONDS KOERS VERSCHIL VERSCHIL % BEURS Galapagos 149,25 21,10 16,47 % Euronext Amsterdam(ABM FN-Dow Jones) Galapagos heeft een heel goede deal met Gilead gesloten. Dit zei analist Corne van Zeijl van Actiam voor de camera van ABM Financial News.Er zit volgens Van Zeijl echter ook "een negatieve kant" aan het verhaal voor beleggers. De overnamekansen voor Galapagos zijn "nihil" geworden.Al met al meent de analist echter dat het positief nieuws is voor Galapagos.www.youtube.com/watch?v=4XcWz5I_jqgDoor: ABM Financial News.info@abmfn.nlRedactie: +31(0)20 26 28 999© Copyright ABM Financial News B.V. All rights reserved. Aanbevelingen 0 ” Quote Reageren Niet oké
avantiavanti 15 juli 2019 12:57 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 SVB Leerink 15 juli 2019Galapagos, Long Recognized as Technical Powerhouse, Rewardedwith Independence Aanbevelingen 4 ” Quote Reageren Niet oké
Wall Street Trader 15 juli 2019 13:12 auteur info Wall Street Trader Lid sinds: 09 aug 2018 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 3455 Gegeven: 1213 Aantal posts: 1.253 quote:Pl4 schreef op 15 juli 2019 12:17:[...]Most of them are wrong.. but they'll catch up later.Filgotinib’s deal term slightly changed.Fair value would be about € 180But a lot of models / price targets are currently under review. Aanbevelingen 0 ” Quote Reageren Niet oké
avantiavanti 15 juli 2019 13:47 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 H.C.Wainwright&Co 15 juli 2019Gilead Opts for Decentralized R&D Model Witha $5.1B Collaboration; Target to $205 From $150 Aanbevelingen 3 ” Quote Reageren Niet oké
avantiavanti 15 juli 2019 13:57 auteur info avantiavanti Lid sinds: 08 mrt 2013 Laatste bezoek: 30 jan 2025 Aanbevelingen Ontvangen: 3209 Gegeven: 2167 Aantal posts: 999 Extract Nomura Instinet 15 juli 2019First Look: Galapagos NV (GLPG US, Buy) - GILD Deal: Best Outcome Short of M and AChristopher Marai, Ph.D. - ILLCOn Sunday, July 14th, GLPG and GILD published a press release and hosted a conference call on a revised R&D collaboration with highly favorable terms for GLPG (PR here, presentation here, collaboration overview here). Briefly, GILD will pay GLPG $3.95bn upfront, and make a $1.1bn investment in the company (consisting of a subscription for new GLPG shares at 140.59 EUR per share, or ~$158.45). This investment increases GILD’s stake to 22% of issued and outstanding shares—however, the collaboration contains a 10-year standstill restricting GILD from trying to increase its stake beyond 29.9%. Overall, the deal is structured to give GILD access to GLPG’s pipeline and to yield some commercial control over filgotinib to GLPG in Europe. The deal also prevents GILD from taking over GLPG for the next 10 years, making this deal the best outcome for GLPG short of full acquisition, in our view. NOTE: our current target price is below the last closing as we evaluate our estimates; our rating remains Buy. Previous GILD/GLPG Deal: Filgotinib-Centric with GILD Taking Commercial Lead and 80:20 Cost Split. In 2016, GILD closed a licensing and collaboration agreement with GLPG for filgotinib. GILD has an exclusive, WW, royalty bearing license for filgotinib and was primarily responsible for development and regulatory approval. GILD was responsible for 80% of costs incurred (and GLPG responsible for 20%). GILD made an upfront license fee payment of $300mn and a $425mn equity investment in GLPG (at the time, representing 14.75% of GLPG’s outstanding share capital). GLPG was eligible to receive regulatory milestone-based payments of up to $755mn, sales-based milestone payments of up to $600mn, and tiered royalties on global net sales from 20-30% (with exception of certain co-promotion territories where profits would be split, which include the UK, Germany, France, Italy, Spain, the Netherlands, Belgium, and Luxembourg). Current Revised GILD/GLPG Deal: Greater GLPG Involvement in Commercializing Filgotinib in Europe, and 50-50 Cost Split; GILD Now Has Rights to GLPG1690 (IPF, Ph3) and GLPG1972 (OA, Ph2b). The new collaboration agreement retains GILDs WW rights and co-development with GLPG in UK, Germany, France, Italy, and Spain. However, GLPG now has exclusive rights in the Netherlands, Belgium, and Luxembourg. In exchange for this expanded commercial role, GLPG will now have to split the costs 50-50 with GILD instead of 20-80. Importantly, GILD now has rights to GLPG pipeline, including outright rights to GLPG1690 for idiopathic pulmonary fibrosis (IPF) and an option for rights on GLPG1972 for osteoarthritis (OA). If ‘1690 is approved, GILD will pay GLPG $325mn; if GILD exercises its option for ‘1972, GILD will pay $250mn after completion of the Ph2b in OA (and an additional $200mn if certain secondary endpoints are met). GLPG would be eligible for $550mn in regulatory and commercial milestones if GILD opts in on ‘1972. Conference Call Focus Was Around GLPG’s R&D Platform and Downplayed Recent Filgotinib Results as Driving Factor. We noted the conference call’s focus was on GILD’s interest in GLPG’s target and drug discovery platform. GILD emphasized their access to GLPG’s IP and programs in inflammation and fibrosis. GILD’s O’Day would not break down how GILD’s investment varied by assets and said that he believe their investment is holistic toward GLPG’s pipeline. In the Q&A, management from both companies downplayed the recent news on filgotinib US filing as an impetus for the deal—O’Day noted long-standing interest on expanding this collaboration (even prior to O’Day joining GILD), and the framework for the deal appears to have been largely set even prior to the recent filgotinib updates. ‘1690 and IPF: High Unmet Need Market with 200K Patients in US and EU; 2017 Sales of Poorly Tolerated Nintedanib and Pirfenidone Was $1.9bn. GILD now has rights to ‘1690, an autotaxin inhibitor to block the bioactive signaling molecule LPA. It is a first-in-class inhibitor of autotaxin. The Ph2b data from FLORA was published in the “The Lancet, Respiratory Medicine). No important safety or tolerability issues were identified, and FVC was stabilized at week 12. With respect to the current collaboration, GILD does not have access to any unblinded data from the ongoing Ph3 studies ISABELLA 1 and 2 but did have unblinded access to safety data. We believe this may be important, as we had previously been concerned about theoretical toxicity from blocking LPA in the CNS. GILD’s interest after seeing unblinded safety data bodes well for the drug, in our view. Recall, this is a high unmet disease population, where 50% of patients die within 2-5 years post-diagnosis. The SOC include pirfenidone and nintedanib, which only slow down decline in lung function and are poorly tolerated (25% discontinuation rate due to AEs). 2016 pricing for pirfenidone and nintedanib was ~$95K/year/patient. Aanbevelingen 3 ” Quote Reageren Niet oké
voda 15 juli 2019 16:13 auteur info voda Lid sinds: 02 dec 2005 Laatste bezoek: 07 feb 2025 Aanbevelingen Ontvangen: 92630 Gegeven: 22746 Aantal posts: 382.850 Beursblik: InsingerGilissen verhoogt koersdoel GalapagosFONDS KOERS VERSCHIL VERSCHIL % BEURS Galapagos 150,60 22,45 17,52 % Euronext Amsterdam(ABM FN-Dow Jones) InsingerGilissen heeft het koersdoel van Galapagos verhoogd van 150,00 naar 200,00 euro met een ongewijzigd Aanbevolen advies. Dit bleek maandag uit een analistenrapport.Volgens analist Jos Versteeg heeft Galapagos een prachtige deal gesloten met Gilead Sciences waarbij het Belgisch-Nederlandse biotechbedrijf zijn zelfstandigheid behoudt.Versteeg wees voor de camera van ABM Financial News op twee belangrijke doelstellingen die Galapagos CEO Onno van de Stolpe heeft: het bedrijf zelfstandig houden en een onafhankelijke Europese farmaceut worden.Dat eerste is door de deal met Gilead gelukt gezien de wapenstilstand van 10 jaar. Volgens Versteeg hoeft Galapagos niet bang te zijn dat er een bod zal komen want Gilead kan zijn belang uitbreiden tot net onder 30 procent en "daarmee is het volstrekt zinloos voor een andere farmaceut om een bod te doen".Het tweede doel van de Galapagos topman, dat wil zeggen een onafhankelijke farmaceut worden, daar heeft hij "ook een grote stap mee gemaakt", vindt Versteeg, omdat Galapagos in de toekomst alle medicijnen in Europa zelf mag ontwikkelen en deels ook vermarkten.Het aandeel Galapagos noteerde maandagmiddag bijna 17 procent hoger op 149,75 euro.Door: ABM Financial News.info@abmfn.nlRedactie: +31(0)20 26 28 999© Copyright ABM Financial News B.V. All rights reserved. Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.